Skip to main content

Table 1 Description of the CHRIS-NAFLD study sample

From: Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study

  Groups
T2Da (N = 173) Non-T2Da (N = 183)
Female—n (%) 84 (48.6) 93 (50.8)
Age (years)—mean (SD) 67.3 (10.4) 67.9 (10.7)
Alcohol consumption (g/day)—median (IQR) 2.0 (0.0, 13.5) 4.9 (1.0, 14.2)
Smoking habits—n (%)
 Never 104 (60.5) 114 (62.3)
 Past 55 (32.0) 59 (32.2)
 Current 13 (7.6) 10 (5.5)
Self-reported diabetes—n (%) 111 (64.2) 1 (0.6)
Diabetes treatment—n (%) 88 (51.8) 0 (0.0)
Systolic blood pressure—mean (SD) 142.1 (19.6) 137.6 (8.7)
Anti-hypertensive treatment—n (%) 109 (63.4) 60 (32.8)
Lipid-lowering agents—n (%) 77 (45.3) 35 (19.9)
Glycated hemoglobin (%)—median (IRQ) 6.4 (6.0, 6.9) 5.3 (5.2, 5.4)
Fasting glucose (mg/dl)—median (IRQ) 122.5 (107.0, 142.0) 90.0 (85.0, 96.0)
Total cholesterol (mg/dl)—mean (SD) 199.5 (43.7) 215.7 (45.9)
HDL (mg/dl)—mean (SD) 53.2 (12.1) 58.6 (13.6)
LDL (mg/dl)—mean (SD) 125.9 (40.2) 135.9 (40.8)
Triglycerides (mg/dl)—median (IRQ) 111.5 (87.5, 143.5) 91.0 (71.0, 122.0)
Proton pump inhibitors—n (%) 19 (11.2) 17 (9.7)
Statins—n (%) 75 (44.1) 35 (19.9)
Body-mass-index (kg/m2)—median (IQR) 30.0 (26.35, 32.7) 25.8 (23.65, 29.0)
Waist circumference (cm)—mean (SD) 100.2 (13.9) 89.5 (12.1)
Body Fat (%)—mean (SD) 35.0 (9.6) 31.1 (10.1)
Visceral Fat (%)—mean (SD) 13.2 (4.8) 10.5 (4.1)
Metabolic syndrome—n (%) 135 (78.0) 45 (24.6)
Hepatic steatosis—n (%)
 Grade 1 56 (32.4) 115 (62.8)
 Grade 2 74 (42.8) 60 (32.8)
 Grade 3 43 (24.9) 8 (4.4)
Controlled attenuation parameter (dB/m)—median (IQR) 263 (223, 315) 234 (186, 266)
Liver stiffness (kPa)—median (IQR) 4.8 (3.7, 5.9) 3.9 (3.3, 5.1)
Visceral adiposity index—median (IQR) 1.46 (1.09, 2.16) 1.07 (0.77, 1.64)
NAFLD liver fat score—median (IQR) 0.20 (− 0.70, 1.13) − 1.90 (–2.25, − 1.24)
Hepatic steatosis score—median (IQR) 41.2 (36.0, 46.0) 34.0 (31.6, 38.1)
Fatty liver index—mean (SD) 41.1 (29.6) 55.2 (28.6)
NAFLD fibrosis score—mean (SD) − 0.55 (1.30) − 1.30 (1.17)
Fibrosis (Fib)-4—median (IQR) 1.22 (0.93, 1.71) 1.43 (1.07, 1.80)
NAFLD classification—n (%) 116 (63.7) 66 (36.3)
  1. aAt CHRIS study baseline